» Articles » PMID: 18323675

Correlation Between Clinical Phenotypes and X-inactivation Patterns in Six Female Carriers with Heterozygote Vasopressin Type 2 Receptor Gene Mutations

Overview
Journal Endocr J
Specialty Endocrinology
Date 2008 Mar 8
PMID 18323675
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

About 90% of patients with congenital nephrogenic diabetes insipidus (NDI) have vasopressin type 2 receptor (V2R) gene mutations that are inherited in an X-linked recessive manner. Although most female carriers are asymptomatic, some female carriers show polydipsia and polyuria. The reason why female carriers show NDI symptoms is explained by skewed X-inactivation. We studied X-inactivation patterns of six female carriers with heterozygote V2R gene mutations. The X-inactivation pattern in peripheral blood leukocytes was examined using methylation analysis of the polymorphic CAG repeat in the androgen receptor gene. Two asymptomatic female carriers showed random X-inactivation (61.9% and 60.7%). Skewed X-inactivation patterns (71.6%, 79.4%, and 91.2%) occurring preferentially to normal X alleles were recognized in three female carriers who showed clinical NDI symptoms. However, in one female carrier who showed clinical NDI symptoms, random X-inactivation (55.4%) was recognized. In conclusion, the clinical NDI phenotypes may correlate with the X-inactivation patterns in female carriers with heterozygote V2R gene mutations. However, in some female carriers, we cannot predict the clinical phenotypes by the evaluation of the X-inactivation patterns in peripheral blood leukocytes, because X-inactivation ratios within an individual are sometimes different between tissues.

Citing Articles

International expert consensus statement on the diagnosis and management of congenital nephrogenic diabetes insipidus (arginine vasopressin resistance).

Levtchenko E, Ariceta G, Arguedas Flores O, Bichet D, Bockenhauer D, Emma F Nat Rev Nephrol. 2024; 21(2):83-96.

PMID: 39438674 DOI: 10.1038/s41581-024-00897-z.


Treatment with ataluren in four symptomatic Duchenne carriers. A pilot study.

Dori A, Scutifero M, Passamano L, Zoppi D, Ruggiero L, Trabacca A Acta Myol. 2024; 43(1):8-15.

PMID: 38586166 PMC: 10997039. DOI: 10.36185/2532-1900-398.


A Novel Missense Mutation of Arginine Vasopressin Receptor 2 in a Chinese Family with Congenital Nephrogenic Diabetes Insipidus: X-Chromosome Inactivation in Female CNDI Patients with Heterozygote 814A>G Mutation.

Zang L, Gong Y, Li Y, Dou J, Lyu Z, Su X Biomed Res Int. 2022; 2022:7073158.

PMID: 35865667 PMC: 9296320. DOI: 10.1155/2022/7073158.


Four Japanese Patients with Congenital Nephrogenic Diabetes Insipidus due to the Mutations.

Namatame-Ohta N, Morikawa S, Nakamura A, Matsuo K, Nakajima M, Tomizawa K Case Rep Pediatr. 2018; 2018:6561952.

PMID: 30073107 PMC: 6057286. DOI: 10.1155/2018/6561952.


Hereditary Nephrogenic Diabetes Insipidus: Pathophysiology and Possible Treatment. An Update.

Milano S, Carmosino M, Gerbino A, Svelto M, Procino G Int J Mol Sci. 2017; 18(11).

PMID: 29125546 PMC: 5713354. DOI: 10.3390/ijms18112385.